Skip to main content
Year archive

Sihuan Pharmaceutical Holdings Group Ltd. — 2023 filings

All 68 regulatory filings released by Sihuan Pharmaceutical Holdings Group Ltd. (460) in 2023, sourced directly from the official regulator.

68 Filings
2023 Period
2023 filings (68)
Filing Released Lang
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Regulatory Filings
2023-12-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Regulatory Filings
2023-11-01 English
VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE INJECTION, DEVELOPED BY HUISHENG BIOPHARMACEUTICAL, APPROVED BY NMPA
Regulatory Filings
2023-10-25 English
VOLUNTARY ANNOUNCEMENT - THE NDA OF CLASS 1 INNOVATIVE DRUG BIROCICLIB'S MONOTHERAPY, INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARM FOR THE TREATMENT OF ADVANCED BREAST CANCER, WAS ACCEPTED BY NMPA
Regulatory Filings
2023-10-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
Share Issue/Capital Change
2023-10-03 English
Notification Letter and Request Form to Non-registered Holder
Report Publication Announcement
2023-09-26 English
Interim Report 2023
Interim / Quarterly Report H1 2023
2023-09-26 English
Notification Letter and Change Request Form to Registered Shareholder
Report Publication Announcement
2023-09-26 English
VOLUNTARY ANNOUNCEMENT - THE NDA OF CLASS 1 INNOVATIVE DRUG BIROCICLIB TABLETS, INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARMACEUTICAL, ACCEPTED BY NMPA
Regulatory Filings
2023-09-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
Regulatory Filings
2023-09-04 English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
Interim / Quarterly Report H1 2023
2023-08-29 English
NOTICE OF BOARD MEETING
Report Publication Announcement
2023-08-17 English
PROFIT WARNING
Regulatory Filings
2023-08-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
Major Shareholding Notification
2023-08-01 English
VOLUNTARY ANNOUNCEMENT - DOPAMINE HYDROCHLORIDE INJECTION OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA
Regulatory Filings
2023-07-06 English
VOLUNTARY ANNOUNCEMENT - HUISHENG BIOPHARMACEUTICAL'S DRUG SEMAGLUTIDE INJECTION OBTAINED APPROVAL FOR CLINICAL TRIAL
Regulatory Filings
2023-07-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
Major Shareholding Notification
2023-07-03 English
VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF XUANZHU BIOPHARMACEUTICAL'S CLASS 1 INNOVATIVE DRUG BIROCICLIB WAS APPROVED FOR PHASE II CLINICAL TRIAL
Regulatory Filings
2023-07-03 English
VOLUNTARY ANNOUNCEMENT - THE INNOVATIVE DRUG ANAPROZOLE SODIUM ENTERIC-COATED TABLETS INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARMACEUTICAL OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA
Regulatory Filings
2023-06-26 English
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
Regulatory Filings
2023-06-16 English
VOLUNTARY ANNOUNCEMENT - HUISHENG BIOPHARMACEUTICAL'S DRUG SEMAGLUTIDE INJECTION IND APPLICATION ACCEPTED BY NMPA
Regulatory Filings
2023-06-13 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-06-07 English
VOLUNTARY ANNOUNCEMENT - AZITHROMYCIN FOR SUSPENSION AND FLUCONAZOLE AND SODIUM CHLORIDE INJECTION OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA
Regulatory Filings
2023-06-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023
Share Issue/Capital Change
2023-06-05 English
AMENDED AND RESTATED BYE-LAWS
Governance Information
2023-06-02 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 2 JUNE 2023
Declaration of Voting Results & Voting Rights Announcements
2023-06-02 English
VOLUNTARY ANNOUNCEMENT - HUISHENG BIOPHARMACEUTICAL'S DRUG MECOBALAMIN TABLETS APPROVED FOR MARKETING BY NMPA
Regulatory Filings
2023-06-01 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-05-25 English
SUPPLEMENTAL ANNOUNCEMENT - SUPPLEMENTAL INFORMATION IN RELATION TO THE 2022 ANNUAL REPORT
Regulatory Filings
2023-05-23 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-05-19 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-05-12 English
VOLUNTARY ANNOUNCEMENT - THE NDA OF INSULIN DEGLUDEC AND INSULIN ASPART INJECTION, DEVELOPED BY HUISHENG BIOPHARMACEUTICAL, ACCEPTED BY NMPA
Regulatory Filings
2023-05-09 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-05-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
Regulatory Filings
2023-05-02 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2022
Environmental & Social Information
2023-04-27 English
Notification Letter and Request Form to Non-registered Holder
Report Publication Announcement
2023-04-27 English
Notification Letter and Change Request Form to Registered Shareholder
Report Publication Announcement
2023-04-27 English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
AGM Information
2023-04-27 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2023-04-27 English
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, DECLARATION AND PAYMENT OF A FINAL CASH DIVIDEND, RE-ELECTION OF RETIRING DIRECTORS, PROPOSED AMENDMENTS TO THE BYE-LAWS AND ADOPT
AGM Information
2023-04-27 English
Annual Report 2022
Annual Report FY 2022
2023-04-27 English
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIALS OF XUANZHU BIOPHARM'S CLASS 1 INNOVATIVE DRUG BIROCICLIB REACHED PRIMARY ENDPOINT
Regulatory Filings
2023-04-26 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-04-25 English
VOLUNTARY ANNOUNCEMENT - XUANZHU BIOPHARM COMPLETED PATIENT ENROLLMENT IN PHASE II CLINICAL TRIALS ON NEW INDICATION OF INDEPENDENTLY DEVELOPED DRUG ANAPRAZOLE SODIUM
Regulatory Filings
2023-04-18 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ESOMEPRAZOLE SODIUM API OBTAINING DRUG REGISTRATION APPROVAL FROM NMPA
Regulatory Filings
2023-04-16 English
VOLUNTARY ANNOUNCEMENT - FAVIPIRAVIR TABLET AND ESOMEPRAZOLE SODIUM API OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA
Regulatory Filings
2023-04-14 English
VOLUNTARY ANNOUNCEMENT - THE SUBMISSION OF PHASE II CLINICAL RESULTS OF XUANZHU BIOPHARMACEUTICAL'S CLASS 1 INNOVATIVE DRUG BIROCICLIB WAS ACCEPTED BY 2023 ASCO ANNUAL MEETING
Regulatory Filings
2023-04-14 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-04-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
Share Issue/Capital Change
2023-04-04 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-03-31 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information
2023-03-31 English
RESIGNATION AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES
Board/Management Information
2023-03-31 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares
2023-03-28 English
VOLUNTARY ANNOUNCEMENT - THE RECOMBINANT HUMAN CD80 MUTANT-Fc FUSION PROTEIN INJECTION AND XZP-6877 TABLETS DEVELOPED BY XUANZHU BIOPHARM WERE APPROVED FOR CLINICAL TRIALS
Regulatory Filings
2023-03-27 English
Risk Management Committee Terms of Reference Adopted by the Board on 13 December 2015 and Amended by the Board on 24 March 2023
Governance Information
2023-03-24 English
VOLUNTARY ANNOUNCEMENT - SIHUAN PHARMACEUTICAL'S FIRST CLASS 1 MACROMOLECULE INNOVATIVE DRUG HER2 BISPECIFIC ANTIBODY ADC XZP-KM501 APPROVED FOR CLINICAL TRIALS
Regulatory Filings
2023-03-24 English
Final Cash Dividend for the year ended 31 December 2022
Notice of Dividend Amount
2023-03-24 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022 AND PROPOSED AMENDMENTS TO THE BYE-LAWS AND ADOPTION OF THE NEW BYE-LAWS
Annual Report FY 2022
2023-03-24 English
NOTICE OF BOARD MEETING
Report Publication Announcement
2023-03-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
Share Issue/Capital Change
2023-03-02 English
VOLUNTARY ANNOUNCEMENT - ABOUT ENTERING INTO THE DRUG COMMISSIONED MANUFACTURING AND SUPPLY AGREEMENT OF COVID-19 TREATMENT DRUG DEUREMIDEVIR HYDROBROMIDE TABLETS
Capital/Financing Update
2023-02-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
Regulatory Filings
2023-02-01 English
VOLUNTARY ANNOUNCEMENT - SIHUAN PHARMACEUTICAL'S PRODUCT MIDAZOLAM OROMUCOSAL SOLUTION INCLUDED IN THE NATIONAL DRUG REIMBURSEMENT LIST 2022
Regulatory Filings
2023-01-26 English
VOLUNTARY ANNOUNCEMENT - TWO NON-PVC SOLID-LIQUID DOUBLE CHAMBER BAG PRODUCT INCLUDED IN THE NATIONAL DRUG REIMBURSEMENT LIST 2022
Regulatory Filings
2023-01-26 English
PROFIT WARNING
Regulatory Filings
2023-01-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
Regulatory Filings
2023-01-04 English
VOLUNTARY ANNOUNCEMENT - SIHUAN PHARMACEUTICAL'S SUBSIDIARY JILIN HUISHENG BIOPHARMACEUTICAL CO., LTD. COMPLETED ROUND A+ FINANCING SUCCESSFULLY
Capital/Financing Update
2023-01-03 English
DISCLOSEABLE AND CONNECTED TRANSACTION - DISPOSAL OF EQUITY INTERESTS IN JILIN JIAHUI CHEMICAL CO., LTD.
Capital/Financing Update
2023-01-03 English